Introduction: We studied the evolution of sensory neuropathy after antiretroviral therapy (ART) in human immunodeficiency virus-infected South Africans. Methods: Enrolment commenced before ART with 6-monthly follow-ups for 24 months. Symptomatic distal sensory polyneuropathy (SDSP) was defined as one symptom and sign. Symptom/sign scores were compared between visits. Results: We enrolled 184 participants. Pre-ART, 16% had SDSP. After 18 months of ART, pain prevalence decreased in those with pre-ART SDSP (odds ratio [OR], 0.09; 95% confidence interval [95%CI], 0.03-0.29). Symptoms improved in 50% ever experiencing pain (mean improvement 5 4.5 on 11-point scale). Participants SDSP-free pre-ART developed SDSP at a rate of 18 per 100 person-years. After 24 months (n 5 102), 18% had SDSP. Stavudine (60% of cohort) did not predict incident SDSP, but associated with increased prevalence of reduced/absent reflexes at 18 months (OR, 2.24; 95% CI, 1.08-4.65). Discussion: Painful symptoms improved during ART. Evolving sensory neuropathy was due to increasing small and large fiber dysfunction.
Sensory neuropathy, comprising painful symptomatic distal sensory polyneuropathy (SDSP) and asymptomatic distal sensory polyneuropathy (ADSP), is a frequent manifestation of human immunodeficiency virus (HIV) infection. Sensory neuropathy has a multifactorial pathogenesis, affecting both small and large sensory fibers.
1,2 SDSP manifests as distal lengthdependent and symmetrical neuropathic symptoms of numbness, paresthesia, and/or burning pain. Painful SDSP is noted in patients with advanced HIV infection, or coincident with symptoms of concomitant tuberculosis (TB) infection, either before or more commonly soon after initiation of TB treatment, 3 or within the first 3-6 months of antiretroviral therapy (ART). Incident SDSP within the first 6 months of ART occurs particularly in those treated with dideoxynucleotide reverse transcriptase inhibitors (e.g., stavudine) and/or with a greater CD4 1 cell recovery. [4] [5] [6] [7] While ADSP is prevalent among individuals before starting ART, the prevalence of ADSP increases over time post-ART initiation. 8, 9 Research has focused on identifying factors that predict sensory neuropathy risk; however, fewer studies have prospectively and longitudinally followed patients from before initiation of ART. Therefore, the evolution and recovery of established neuropathic symptoms and signs during ART is not well described. Evans et al. (2011) followed a study cohort prospectively but these participants entered the study at varied times after starting ART. 8 Another prospective cohort from sub-Saharan Africa followed participants for 6 months after ART initiation and reported the resolution of neuropathic symptoms in 22% and signs in 23%. 10 This study describes the evolution of sensory neuropathy during the first 2 years of ART in a community-based cohort of black South Africans enrolled in a government-run HIV treatment program. We focused on the response of pre-existing HIV-associated SDSP to ART initiation, the incidence of SDSP after ART initiation, comparing stavudine versus non-stavudine-containing regimens and other risk factors, and the temporal evolution of sensory symptoms and signs.
PATIENTS AND METHODS
Study Design, Setting, and Population. Over a 1.5-year period HIV-infected patients scheduled to commence ART within the following 7 days were recruited from the HIV clinic at Crossroads Community Health Centre in Cape Town, South Africa. Patients attend this clinic on an outpatient basis and are, therefore, generally medically stable. The primary demographic is black, predominantly Xhosaspeaking South Africans.
Participants were eligible if 18 years, had confirmed HIV infection, and met criteria for ART initiation in the . Study entry exclusion criteria were known diabetes mellitus, serious systemic illness, severe diarrhea, comorbid neurological disease, TB treatment initiated within the preceding 2 months, exposure to glucocorticoids within the preceding 6 months, and pregnancy.
The University of Cape Town Research Ethics Committee approved this prospective longitudinal cohort study. Participants provided written informed consent to participate.
Participant Assessment. Participants were examined before the initiation of ART (referred to as baseline), and 3, 6, 12, 18 and 24 months thereafter, or until loss to follow-up. At each visit, participants underwent a basic examination including resting blood pressure, focused neuropathy examination, anthropometrical assessments, and metabolic analyses (fasting glucose, insulin, cholesterol, triglycerides, low density lipoprotein, and high density lipoprotein). Clinical, medication, and alcohol use history and other laboratory data were obtained from chart review and participant interview. Alcohol use was defined as any alcohol intake during the previous year.
2 Laboratory data obtained from chart review consisted of baseline creatinine, alanine transferase, hemoglobin, white cell count, baseline/pre-ART and 24-week CD4 1 cell count, and 24-week viral load (baseline viral loads were not routinely performed in South African government-run HIV programs).
The focused neuropathy examination was performed by one of four clinicians (C.M.C., J.J.v.d.W., J.-R.V., and J.M.H.) using the Brief Peripheral Neuropathy Screen (BPNS) 11 and a reduced version of the Total Neuropathy Score (TNSr) as previously described. 2 Worst pain, paresthesia, and numbness symptom severity were subjectively assessed on a visual numerical rating scale (NRS) from 0 to 10 using a Xhosa-translated symptom questionnaire as part of the BPNS tool. 2 The anatomical extent of symptoms (any of pain, paresthesia, or numbness) were also scored according to the TNSr and included no abnormality (0), involvement of the toes and/or soles of feet only (1), extending to the ankles (2), knees (3), and extending above the knees and/or including hands (4) . The neuropathy examination included assessments of vibratory and pinprick sensation, and tendon reflexes as part of the BPNS and TNSr. The anatomical extent of vibration and pinprick sensation impairment was scored from 0 to 4 according to the TNSr as for symptoms above. Reflexes were scored as normal (0), reduced ankle jerks (1), absent ankle jerks (2), absent ankle jerks and others reduced (3) , and all reflexes absent (4). In addition, position sensation was evaluated at the big toe and abnormal position sensation defined as >20% mistakes (out of 10 trials). All abnormal scores required bilateral symmetrical involvement.
Definitions. The diagnosis of SDSP required the presence of 1 sensory symptom (pain, paresthesia or numbness) with 1 neuropathic sign (impaired vibration sensation, impaired pinprick sensation, or reduced/absent reflexes). ADSP was defined by the presence of 1 neuropathic sign in the absence of sensory symptoms. Incident SDSP was defined as no symptoms at baseline with development of SDSP after ART initiation. Worsening symptoms were denoted by at least 2-point increase in NRS, whereas improvement was denoted by at least 2-point decrease in NRS. 12 At least 1-point change in TNSr denoted either worsening or improvement of sensory symptoms and neuropathic signs.
Statistical Analysis. Stata 12.0 (StataCorp. College Station, Texas) was used for the statistical analysis. The participant characteristics and neuropathy scores at baseline (pre-ART) and at 24 months were described by proportions or medians with interquartile range (IQR). Differences between the SDSP group and SDSP-free group were compared using the chi-square test and Wilcoxon rank-sum test. Multiple logistic regression predicted baseline SDSP in a model that included the significant risk factors (P < 0.05) of participant age (per unit increase), previous/current TB, waist:hip ratio (per 0.01 unit increase), and triglyceride levels (per 0.1 unit increase). An odds ratio (OR) and 95% confidence interval (CI) was estimated for each covariate. A multivariate Cox-proportional hazards regression model was used to predict onset of incident SDSP in participants who were SDSP-free at baseline, and used age 40 and fasting insulin as covariates. Data were assumed to be uninformatively censored. The hazard ratio (HR) and 95% CI are presented. The magnitude of symptom NRS and TNSr improvement/worsening over time was estimated by the mean score difference (with standard errors) between 2 visits (from the first observation of the abnormality until the last observation) for each symptom and sign in all participants ever experiencing the abnormality.
Population average logistic regression models, assuming an exchangeable within-subject correlation structure, were used to model the prevalence of symptoms and signs at each visit. Prevalence was compared with baseline in the whole cohort, and then in and between groups. Model A compared the group that entered the study with SDSP versus the group that entered the study SDSP-free; and Model B compared the group that received a stavudine-containing regimen versus a non-stavudine-containing regimen. As a result of nonmonotonic nonlinear time profiles, time was treated as a categorical variable and modeled as a dummy variable that compared prevalence at follow-up visits to that at baseline. The model was plotted and estimated ORs and 95% CIs reported. Because of missing data, the 24-month visit was excluded from the analysis and models were repeated on imputed data; results for the analysis done on the imputed data supported the analysis done on the unimputed data.
RESULTS
Baseline Characteristics. One hundred and ninety patients were enrolled in the study. Two participants were excluded as they did not commence ART within 2 weeks of the baseline (pre-ART) assessment. One participant was excluded because of asymmetrical neuropathic signs on examination and three withdrew consent. The baseline study sample, therefore, comprised 184 participants.
The baseline assessment was performed a median of 1 day before initiation of ART (IQR 1-5). The study population was predominantly women (70%), with a median age of 33 years (Table 1, Supplementary Table S1 , which is available online). Overall, 38% had a history of previous or current TB treatment; 57% of this group had completed TB treatment before study entry, while 43% were receiving treatment at study entry. Only seven of those on TB therapy (23%) were receiving 25 mg vitamin B6 supplementation. The median CD4 1 cell count was 156 cells/mm 3 . At study entry, almost all participants ( 95%) were also receiving cotrimoxazole and vitamin Bcomplex supplements.
Follow-up Characteristics. Among the 184 participants who were examined at baseline (pre-ART), 160 (86%) had at least one follow-up assessment and 102 (55%) completed 24 months of follow-up. The median attrition rate per visit was 12%. Participants who were lost to follow-up did not differ significantly from those who remained in the study when comparing baseline characteristics and baseline sensory neuropathy status between the two groups (data not shown).
Of those with follow-up data, 100 (61%) participants began ART with a stavudine-containing regimen, 46 (28%) with a tenofovir-containing regimen and 18 (11%) with a zidovudinecontaining regimen. ART data are missing for 1 participant. Eight participants started TB treatment after study entry. At 6 months, viral control (viral load < 20 copies/ml) was noted in 82 participants (86%) and CD4 1 cell counts improved from a median of 156 (IQR, 113-195) cells/mm 3 at baseline to 261 (IQR, 190-365) cells/mm 3 . At 24 months, less than half the cohort (48%) remained on cotrimoxazole and vitamin Bcomplex supplements with similar proportions among those with or without SDSP (Supplementary Table S1 ). There were no participants on anti-TB drugs and only two were receiving vitamin B6 (25 mg) supplementation.
Neuropathy before ART Initiation. Before ART initiation, 30 (16%) participants had SDSP and 73 (39%) had ADSP. Table 1 and Supplementary  Table S1 compare the clinical and laboratory characteristics between baseline (pre-ART) SDSP and SDSP-free groups. Significant associations were age, waist:hip ratio, previous and current TB treatment, and higher triglyceride levels. Risk factors independently associated with baseline SDSP were previous or current TB treatment (adjusted OR, 5.4; 95% CI, 1.9-15.2) and higher triglyceride levels (OR, 5 1.1 per 0.1 unit increase, 95% CI, 1.0-1.3). No baseline characteristics showed a significant association with ADSP (data not shown).
In participants with pre-ART SDSP, pain and paresthesia were present in 83%; pain was reported to be moderate-to-severe (NRS 4) in 76% of those with pain (Supplementary Table S2 ). Impaired pinprick sensation was more frequent in SDSP observations than in ADSP observations (83% vs. 33%; P < 0.001). In 30% of SDSP observations, abnormal pinprick sensation was the only abnormal sign elicited. Impaired vibration sensation was also more frequent in the SDSP group than in the ADSP group (P 5 0.015). Altered position sense in the toes was evident in 17 (9%) and similar in those with or without neuropathic symptoms. Before ART initiation, 7 (4%) participants had neuropathic symptoms in the absence of neuropathic signs.
Incident Symptomatic DSP after ART Initiation and Risk Factors. In participants who were SDSP-free at baseline, incident SDSP occurred at a rate of 17.8 per 100 person-years; 95% CI, 12.7-25.1), with a higher rate of incident SDSP during the first 6 months (46.0 per 100 person-years; 95% CI, 30.9-69.9). Incident SDSP was associated with age 40 years (HR, 3.0, 95% CI, 1.5-6.1) and inversely associated with fasting insulin levels (HR, 0.8; 95% CI, 0.6-1.0). On multivariate analysis, the association with fasting insulin remained significant (adjusted HR, 0.8; 95% CI, 0.6-1.0), but the association with age did not. Use of stavudine also did not significantly predict onset of SDSP (HR, 1.4; 95% CI, 0.7-2.7), nor did ADSP at baseline (HR, 1.6; 95% CI, 0.8-3.2).
Of the 102 participants remaining in the study at the 24-month evaluation, 18 (18%) had SDSP and 63 (62%) ADSP (Table 1 and Supplementary  Table S1 ). At this final visit, SDSP was associated with older age and higher glucose levels after the oral glucose tolerance test. In contrast to the baseline (pre-ART) association, the fasting triglyceride levels were similar between the SDSP and SDSPfree group.
Evolution of Neuropathic Symptoms and Signs.
Individual neuropathic scores (NRS for symptoms, TNSr for symptoms and signs) were evaluated longitudinally from the first observation of an abnormality until censoring (Table 2) . Pain scores showed improvement in over 50% of participants ever experiencing pain; the mean improvement in the NRS (among those who did improve their scores) was 4.5 and the mean improvement in TNSr was 1.6. Only a minority (9%) experienced worsening of pain. Improvement in pinprick and vibration sensation scores was noted in 37% and 40%, respectively, while fewer (29%) showed improvement in reflexes. Abnormal position sensation at the distal toes was detected in two cases with ADSP (2%) by 24 months.
The prevalence of symptoms and signs at follow-up visits was compared with baseline (pre-ART) prevalence in the overall cohort ( Fig. 1 ; Table 3 ). The prevalence of symptoms remained statistically unchanged throughout the study, aside from an isolated increase at the 3-month visit for paresthesia and numbness. In contrast, the prevalence of signs was higher at almost all follow-up visits. The prevalence of symptom and sign at followup visits was compared with baseline prevalence in and between groups: (A) group that entered the study with SDSP versus group that entered the study SDSP-free; and (B) group initiated on a stavudine-containing regimen versus group initiated on a non-stavudine-containing regimen. In analysis A, the prevalence of pain and paresthesia was noted to decrease at each follow-up visit in the baseline SDSP group (month 18 vs. month 0; OR, 0.09; 95% CI, 0.03-0.29), while symptom prevalence increased in the SDSP-free group ( Fig. 2A ; Supplementary Table S3 ). The prevalence profiles for symptoms differed significantly between the two groups at all follow-up visits. Prevalence of signs increased significantly in the baseline SDSP- Table 2 for estimated ORs and 95% CIs. free group, while prevalence of signs in the baseline SDSP group remained relatively statistically unchanged, aside for an initial drop in prevalence at 3 months for abnormal pinprick sensation and an increase at 6 months for reduced/absent reflexes. Overall, the profiles for abnormal pinprick sensation differed significantly between the baseline SDSP versus SDSP-free groups at all follow-up visits.
In analysis B, participants who received stavudine had a higher baseline prevalence of pain compared with those who were started on a nonstavudine-containing regimen ( Fig. 2B ; Supplementary Table S4 ). These patients also had lower CD4 1 cell counts, because the governmentsponsored ART program enrolled participants with lower CD4 1 cell counts [200/mm 3 ] while stavudine was in use, whereas the switch to tenofovir cooccurred with starting ART when CD4 1 cell counts were higher [350/mm 3 ]. Nevertheless, symptom prevalence did not differ significantly between the two groups thereafter. Both groups experienced an increasing prevalence of signs, but the increase in prevalence for reduced/absent reflexes was significantly greater in the stavudine group for months 6, 12 and 18 (OR, 2.24; 95% CI, 1.08-4.65 for stavudine vs. non-stavudine at 18-months). An analysis comparing the group with baseline CD4 1 cell count 200/mm 3 versus the group with CD4 1 cell count > 200/mm 3 did not demonstrate the same effects (data not shown).
In an exploratory analysis, we compared participants who entered the study with ADSP to those who entered the study free of both ADSP and SDSP ( Supplementary Fig. S1 ). This analysis showed a trend for a higher proportion of the ADSP group to have painful symptoms at follow-up at visits when compared with those free of both ADSP and SDSP pre-ART. However, the survival analysis did not significantly support this observation.
DISCUSSION
We found SDSP in 16% and ADSP in 39% of ART-na€ ıve patients immediately before starting ART, suggesting a substantial background prevalence of pre-existing HIV-associated sensory neuropathy. Pre-ART SDSP was independently associated with current or previous TB / TB treatment and higher fasting triglyceride levels. Although older age is frequently identified as a risk factor for HIV-associated DSP, it did not remain associated with SDSP in a multivariate analysis. We and others have found a high prevalence of sensory neuropathy in HIV/TB co-infected patients in similar settings. 3, 13 Earlier initiation of ART may reduce the high prevalence of sensory neuropathy demonstrated in this study by reducing exposure to HIV-induced oxidative stress 6 and coinfection with TB. It is worth mentioning that only a minority of participants enrolled in this study were prescribed supplementary vitamin B6 by the clinic during TB treatment. 7 Supplementation with vitamin B6 has been shown to prevent the sensory neuropathy associated with isoniazid.
14 Although vitamin B12 deficiency has been reported in 10% in a similar population, 15 we found macrocytic anemia (a proxy for vitamin B12 deficiency) in only three participants at baseline.
There were some "metabolic" signals which associated with SDSP in this black, relatively young African cohort (which characteristically comprises predominantly women).
1,2 We replicated our previous observations that higher waist:hip ratios (univariate analysis) and fasting triglycerides levels associated with SDSP pre-ART. 2 Although the latter association has been observed in an ART-treated cohort, 16 we did not demonstrate higher fasting triglyceride levels in SDSP after 24 months of ART. It is unclear whether the substantially lower level of absolute fasting triglycerides in our African cohort compared with nonfasting results from firstworld cohorts 16, 17 is due to the timing of the blood draws, or whether it suggests the absolute triglyceride level is not itself critical, but rather a surrogate biomarker for painful neuropathy. The latter explanation is supported by the plateau in prevalence of painful SDSP after 6 months of ART coupled with the loss of the association signal between SDSP and fasting triglycerides at 24 months.
Our results confirm that patients are most at risk of developing SDSP either before or within the first 3 to 6 months of initiating ART. 4, 6 FIGURE 2. Modeled prevalence of neuropathic symptoms and signs at each visit over 18 months in and between groups: group that entered the study with baseline (pre-ART) SDSP ("1") and group that entered the study free of SDSP ("0") (A); and group that received a stavudine-containing regimen ("1") and group that received a non-stavudine-containing regimen ("0") (B). *Significant difference in prevalence between indicated visit and baseline visit. **Significant difference in prevalence profile between groups at indicated visit. Refer to Supplementary Tables S3 and S4 for estimated ORs and 95% CIs.
Incident SDSP (in those SDSP-free at study entry) occurred at a higher rate during the first 6 months (46 per 100 person-years) compared with the overall study period (18 per 100 person-years). The onset of SDSP coincided with the time window in which a potentiation of dysregulated systemic inflammatory signals has been observed after ART initiation, irrespective of the pre-ART CD4 1 cell count. 6, 18 Incident SDSP was inversely associated with fasting insulin. Insulin has been shown to exert a regenerative effect and improve mitochondrial function in vitro. 19, 20 Noninsulin glucoselowering drugs have also been shown to have a neuro-protective effect in HIV-associated sensory neuropathy. 21 It is noteworthy that our patients had not received statins or hypoglycemic medications. Intriguingly, patients with painful SDSP do not respond to standard symptomatic therapies that provide relief in similarly painful diabetic and other neuropathies. 1, 22, 23 Although some symptomatic participants in this study received therapies for pain (35% of symptomatic visits; mainly amitriptyline), the study design precluded estimation of potential benefit of these therapies.
While a small proportion (9-13%) of participants experienced mild-to-moderate worsening of their symptoms over time, more than half experienced a substantial improvement in their symptoms with a mean absolute decrease in worst pain score of 4.5 (on an 11-point scale) and a proximal regression in anatomical extent (as measured by the 4-point TNSr scale). Experimental models suggest that painful symptoms are driven and maintained by exposure to HIV proteins such as gp120 and HIV-induced inflammatory cascades in the nerve cell body and axon. 1, 24 Viral clearance and the relative stabilization of immune dysregulation with successful ART may potentially account for the reduction in the HIVassociated small fiber painful neuropathic symptoms seen in participants with pre-existing HIV-associated SDSP. These results underscore the benefit anticipated from earlier ART initiation.
In contrast to the predominant improvement in symptoms, improvement of neuropathic signs was observed less frequently and the prevalence of signs in the overall cohort increased significantly at each visit. By 24 months, the proportion of participants with ADSP increased from 39% at baseline (pre-ART) to 62%, a finding in keeping with previous reports of ADSP in long-term cohorts. 8 The accumulation of clinical evidence of nerve dysfunction may be attributed to the slow transport of dysfunctional mitochondria down axons over months to years and the particular susceptibility of distal sensory axons to mitochondrial defects. 25, 26 Of interest, despite the increasing prevalence of neuropathic signs sub-served by small (pinprick) and larger myelinated sensory fibers (reflexes and vibration), position sensation loss stayed low in the first 2 years after ART initiation. It remains to be seen whether early inflammation will impact on subsequent mitochondrial dysfunction; however, our data do not suggest that those with early SDSP subsequently accumulate neuropathic signs.
The study provided a unique opportunity to prospectively compare sensory neuropathy between patients treated with a dideoxynucleotide reverse transcriptase inhibitor (stavudine) and those treated with other classes of antiretrovirals, as the study coincided with the phase-out of stavudine and the introduction of tenofovir-containing regimens in first-line ART regimens in South Africa. The use of stavudine did not significantly predict the onset of SDSP, but did result in increasing prevalence of reduced/absent reflexes compared with the nonstavudine group. The clinical relevance of impaired reflexes is uncertain. It should be noted that participants who were started on stavudine (as per program guidelines) had a higher prevalence of painful symptoms before commencing ART, possibly because of lower CD4 1 cell counts seen before the phase-out of stavudine. These patients may have been identified using a routine symptom screen. 27 During this study, none of the patients were switched by their clinic health workers from their initial first-line regimen.
As mentioned, abnormal pinprick sensation was noted in a high proportion with SDSP, similar to our previous findings 2 ; in a third, impaired pinprick sensation was the only neuropathic sign elicited. The BPNS, used in many studies, excludes this easy to perform bedside test of small fiber function, potentially missing DSP in several patients. 3 Although this modality has utility in resource-limited settings lacking tools and expertise for proper assessment of vibration sensation and reflexes, our results suggest that the symptomonly screening tool 27 will over call SDSP in only a small subset (4%) who had isolated neuropathic symptoms in the absence of signs.
The study experienced loss-to-follow-up at a rate of 12% per visit. Some loss-to-follow-up may have been attributed to migration or limited access. An analysis of baseline characteristics and outcomes between patients who remained in the study and those lost to follow-up at each visit suggested that this loss was at random; 28 however, attrition bias cannot be excluded. We used a mixed-effect model that accounts for loss-to-follow-up in the longitudinal analysis and performed an imputed longitudinal analysis that produced similar results to an unimputed analysis (data not shown).
This cohort was substantially smaller than the multi-centered North American cohorts; 8, 9, 21 however, strengths of the study include prospective longitudinal assessments from just before starting ART, study visits at regular time intervals thereafter, and examination by the same doctors, thereby minimizing inter-rater bias. 29 In this prospective study, we used a DSP definition of at least 1 neuropathic sign as we were assessing signs from a known baseline, which improved specificity without having to use stricter criteria, and allows for comparison with other studies. All metabolic and lipid parameters were assessed in a fasting state. A limitation may be that a history of diabetes at baseline resulted in exclusion from this study, but despite this exclusion there was an association between SDSP and higher glucose levels after the oral glucose tolerance test after 2 years of ART. This observation requires careful attention in the follow-up of these cases in HIV treatment programs. The relatively advanced immunosuppression observed in this study (median pre-ART CD4 1 cell count 5 156 cells/mm 3 ), which also resulted in high proportions of concomitant cotrimoxazole use at ART initiation, limits generalizability of these data to cohorts initiating ART at higher CD4 1 cell counts.
In conclusion, we have studied the clinical evolution of neuropathic symptoms and signs in a typical African community-based cohort comprising predominantly younger women with relatively advanced HIV-infection at the time of ART initiation. Neuropathic pain largely improved in response to ART, although a proportion developed new painful neuropathic symptoms. Increasing prevalence of neuropathic signs without symptoms appeared to be related to the accrual of both small and large fiber dysfunction.
